Pi Network's token price fell to a new all-time low near $0.10 in July 2026, pressured by 103.7 million tokens unlocking, increasing potential sell supply. The project counters this with new Pi2Day product launches designed to create real token utility and demand, including a fee-based verification tool, hosting, and sign-in services. The token's near-term direction hinges on whether these products can generate enough demand to absorb the unlocked tokens. Key price levels to watch are $0.10 as critical support and $0.12 as resistance; breaking below $0.10 could lead to further declines, while reclaiming $0.12 might trigger a recovery. Adoption metrics of the new products will be crucial indicators of the token's future trajectory.
Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the pric...
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...
Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew...
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
